Mangoceuticals, Inc. (MGRX) SEC filings

MGRXNasdaqServices-Misc Health & Allied Services, NECFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 7/30

$0.15−0.03 (-16.22%)

Close on Nov 13, 2026Market cap $3.34MP/E –Yield –

SEC filings

40 of Mangoceuticals's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	8-K	Nov 6, 2026	Nov 13, 2026	SEC EDGAR
Current report	8-K	Nov 2, 2026	Nov 6, 2026	SEC EDGAR
Current report	8-K	Oct 8, 2026	Oct 9, 2026	SEC EDGAR
Current report	8-K	Sep 30, 2026	Oct 1, 2026	SEC EDGAR
Current report	8-K	Aug 19, 2026	Aug 21, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 13, 2026	SEC EDGAR
Current report	8-K	Aug 4, 2026	Aug 4, 2026	SEC EDGAR
Current report	8-K	Jul 28, 2026	Jul 30, 2026	SEC EDGAR
Current report	8-K	Jun 29, 2026	Jul 2, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 19, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Apr 1, 2026	SEC EDGAR
Current report	8-K	Mar 16, 2026	Mar 17, 2026	SEC EDGAR
Current report	8-K	Feb 23, 2026	Feb 23, 2026	SEC EDGAR
Current report	8-K	Feb 19, 2026	Feb 19, 2026	SEC EDGAR
Current report	8-K	Feb 4, 2026	Feb 6, 2026	SEC EDGAR
Current report	8-K	Dec 18, 2025	Dec 19, 2025	SEC EDGAR
Current report	8-K	Dec 17, 2025	Dec 19, 2025	SEC EDGAR
Current report	8-K	Dec 4, 2025	Dec 10, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 14, 2025	SEC EDGAR
Quarterly report, amended	10-Q/A	Jun 30, 2025	Nov 14, 2025	SEC EDGAR
Current report	8-K	Nov 13, 2025	Nov 14, 2025	SEC EDGAR
Current report	8-K	Nov 13, 2025	Nov 13, 2025	SEC EDGAR
Current report	8-K	Sep 15, 2025	Oct 29, 2025	SEC EDGAR
Current report	8-K	Sep 9, 2025	Sep 12, 2025	SEC EDGAR
Current report	8-K	Aug 26, 2025	Sep 2, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 14, 2025	SEC EDGAR
Current report	8-K	Jul 30, 2025	Aug 4, 2025	SEC EDGAR
Current report	8-K	Jun 10, 2025	Jul 23, 2025	SEC EDGAR
Current report	8-K	Jul 3, 2025	Jul 10, 2025	SEC EDGAR
Current report	8-K	Jul 1, 2025	Jul 3, 2025	SEC EDGAR
Current report	8-K	Jun 2, 2025	Jun 10, 2025	SEC EDGAR
Current report	8-K	May 15, 2025	May 30, 2025	SEC EDGAR
Current report	8-K	May 22, 2025	May 23, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 15, 2025	SEC EDGAR
Current report	8-K	Apr 28, 2025	May 6, 2025	SEC EDGAR
Current report	8-K	Apr 24, 2025	Apr 25, 2025	SEC EDGAR
Current report	8-K	Apr 11, 2025	Apr 17, 2025	SEC EDGAR
Current report	8-K	Apr 10, 2025	Apr 11, 2025	SEC EDGAR
Current report	8-K	Mar 28, 2025	Apr 8, 2025	SEC EDGAR
Current report	8-K	Mar 28, 2025	Apr 2, 2025	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Mangoceuticals's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-15 reverse split on Oct 16, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is MGRX.

Compare: MGRX vs BRTX · MGRX vs BICX · MGRX vs MCTA · MGRX vs MWAI · MGRX vs NXL

Revenue growth-38.9% · median 34.1%

Gross margin54.4% · median 87.3%

Operating margin-3829.0% · median -3680.5%

Net margin-4791.3% · median -3235.1%

Company	Revenue	Growth
BRTX	$357.87K	-8.5%
MGRX	$315.23K	-38.9%
NXL	$277.31K	+76.7%
BICX	–	–
MCTA	–	–
MWAI	–	–

Company

Exchange: Nasdaq
Industry: Services-Misc Health & Allied Services, NEC
Fiscal year ends: December 31
Held by institutions: 5.6%
Auditor: Turner, Stone & Company, L.L.P.
SEC CIK: 1938046

Advertisement
300 × 250

See a number that looks wrong?